A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BC / breast cancer

[Related PubMed/MEDLINE]
Total Number of Papers: 5937
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BC  (>> Co-occurring Abbreviation)
Long Form:   breast cancer
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Comparative Study of HOTAIR Expression in Breast Cancer Patient Tissues and Cell Lines. lncRNA, qRT-PCR, ROC
2020 A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women. TN
2020 A dose-response meta-analysis of green tea consumption and breast cancer risk. ARP, GT
2020 A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics. ---
2020 A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. ADC, DLT, MTD, PR
2020 A quantitative comparison of arm activity between survivors of breast cancer and healthy controls: use of accelerometry. DASH
2020 A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results. GPs, OC
2020 A seven-DNA methylation signature as a novel prognostic biomarker in breast cancer. AUC, DAVID, DMGs, DMSs
2020 A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. CSCs
10  2020 Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis. ROC
11  2020 Active fraction of Polyrhachis vicina Rogers (AFPR) suppressed breast cancer growth and progression via regulating EGR1/lncRNA-NKILA/NF-kappaB axis. AFPR, TCM
12  2020 Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer. AI
13  2020 Adherence to endocrine therapy and its relation to disease-free survival among breast cancer patients visiting an out-patient clinic at Khartoum Oncology Hospital, Sudan. AIs, DFS, PR, TAM
14  2020 Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. AET, CRN, KPNC
15  2020 An autoantibody against a 48-Kd fragment of human DNA-topoiomerase I in breast cancer: Implication for diagnosis and prognosis, and antibody-dependent cellular cytotoxicity in vitro. ADCC, NK, PBMCs, TAA
16  2020 An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway. MT, p-AKT, WT
17  2020 An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. EORTC, QOL
18  2020 An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer. miRs, TNBC, TS
19  2020 Analysis of circular RNA-associated competing endogenous RNA network in breast cancer. circRNAs, miRNA
20  2020 Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique. FBC
21  2020 Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights. AR, PC
22  2020 Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. AIC, HF, LVEF
23  2020 AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer. AR, PR
24  2020 Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. BCSS, CP, DDFS, GS, OS
25  2020 Association between healthy lifestyle score and breast cancer. BMI, HEI-2010, HLS, PA
26  2020 Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. CVD, CVDRF, HR, SEER
27  2020 Association of Omentin-1 with Oxidative Stress and Clinical Significances in Patients with Breast Cancer. MDA, qRT-PCR, TAC, TOS
28  2020 Association of TGF-beta1 Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies †. CI, OR
29  2020 Association of the genetic variants (-794 CATT5-8 and -173 G>C) of macrophage migration inhibitory factor (MIF) with higher soluble levels of MIF and TNFalpha in women with breast cancer. CS, MIF
30  2020 Attenuated Total Reflection-Fourier Transform Infrared (ATR-FTIR) Spectroscopy Analysis of Saliva for Breast Cancer Diagnosis. ATR-FTIR
31  2020 Bioinformatics Analysis of Metabolomics Data Unveils Association of Metabolic Signatures with Methylation in Breast Cancer. ER, pam, PAM, SAM
32  2020 Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate. CYT
33  2020 BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients. ---
34  2020 Breast Cancer Awareness among Female School Teachers in Saudi Arabia: A Population Based Survey. ---
35  2020 Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. BCRF, BCRP
36  2020 Breast cancer mortality trends in Europe among women in perimenopausal and postmenopausal age (45+). EU, WHO
37  2020 Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. PY
38  2020 Breast cancer: an update on treatment-related infertility. CTRI, GnRHa, OLCs, OSCs
39  2020 Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology. BDen, BVol, GVol
40  2020 Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers. NSM, RRM
41  2020 Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report. ET, pCR
42  2020 Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment. ER, ET, SERM
43  2020 Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling. EMT, PKC, PMA
44  2020 Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. HER2, pOR
45  2020 CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. M2-MPhi, TAMs
46  2020 CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS2a-PDT and Docetaxel-Chemotherapy for Efficient Killing of Breast Differentiated and Stem Cancer Cells In Vitro. CSCs, DTX, HA, PDT
47  2020 CDK4/6 inhibitors in breast cancer - from invitro models to clinical trials. ---
48  2020 Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care. AUC, FBC
49  2020 Characterization of lncRNA LINC00520 and functional polymorphisms associated with breast cancer susceptibility in Chinese Han population. OR, OR, SNPs
50  2020 Chemosensory bitter taste receptors T2R4 and T2R14 activation attenuates proliferation and migration of breast cancer cells. ---
51  2020 Circular RNA 0007255 regulates the progression of breast cancer through miR-335-5p/SIX2 axis. miR, OCR, qRT-PCR, SIX2
52  2020 Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1alpha/HK2. circRNAs, HIF-1alpha
53  2020 Circular RNA; a new biomarker for breast cancer: A systematic review. circRNAs
54  2020 Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer. lncRNAs, NAC
55  2020 Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. BQ, QOL
56  2020 Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. CTCs, PBMC, PBMCs, PFS, TILs
57  2020 Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. BCSS, ER, HR, PR
58  2020 Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant. KOHBRA, OC
59  2020 Combined Effects of Eicosapentaenoic Acid and Adipocyte Renin-Angiotensin System Inhibition on Breast Cancer Cell Inflammation and Migration. ACEI, CAP, CM, EPA, RAS
60  2020 Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. ATC, NAC, pCR, TILs, TNBC
61  2020 Comparison of round smooth and shaped micro-textured implants in terms of quality of life and aesthetic outcomes in women undergoing breast reconstruction: a single-centre prospective study. QOL
62  2020 Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer. AR, PC
63  2020 Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. AI, AIMSS, CAM
64  2020 Complex Mitochondrial Dysfunction Induced by TPP+-Gentisic Acid and Mitochondrial Translation Inhibition by Doxycycline Evokes Synergistic Lethality in Breast Cancer Cells. alpha-KGDHC, DMKG, ETC, mAsp, pgc1alpha
65  2020 Correlation between a variable number tandem repeat (VNTR) polymorphism in SMYD3 gene and breast cancer: A genotype-phenotype study. IHC, SMYD3, VNTR
66  2020 Correlation of MLH1 polymorphisms, survival statistics, in silico assessment and gene downregulation with clinical outcomes among breast cancer cases. MMR, RT-PCR
67  2020 Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. ADRs, TZM
68  2020 Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma. HL, ICUR, MRI, QALYs
69  2020 Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis. cmIF, TILs, TNBC
70  2020 Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor beta1 Are Inversely Associated with Survival in Primary Breast Cancer. HER2, THRbeta1
71  2020 Cytoplasmic PPARgamma is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. ---
72  2020 Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer. CAM, EMT, TNBC
73  2020 Development of Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk. FFPE, MR
74  2020 Diagnostic and prognostic value of the cancer-testis antigen lactate dehydrogenase C4 in breast cancer. CTA, LDH-C4
75  2020 Differentially Expressed Genes in Matched Normal, Cancer, and Lymph Node Metastases Predict Clinical Outcomes in Patients With Breast Cancer. DEGs, KEGG
76  2020 Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence. ROC
77  2020 Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. GC, GHP
78  2020 Distinct trajectories of fruits and vegetables, dietary fat, and alcohol intake following a breast cancer diagnosis: the Pathways Study. F/V
79  2020 Dormancy and NKG2D system in brainmetastases: Analysis of immunogenicity. LC, NKG2D, NKG2DL
80  2020 Down-regulated lncRNA SBF2-AS1 inhibits tumorigenesis and progression of breast cancer by sponging microRNA-143 and repressing RRS1. lncRNAs, miRNAs, RRS1, SBF2-AS1
81  2020 Downregulation of LINC01140 is associated with adverse features of breast cancer. LINC01140, miR
82  2020 Downregulation of miR-302b is associated with poor prognosis and tumor progression of breast cancer. miRNAs, qRT-PCR
83  2020 Dual receptor-targeted (DRT) radiation nanomedicine labeled with 177Lu is more potent for killing human breast cancer cells that co-express HER2 and EGFR than single receptor-targeted (SRT) radiation nanomedicines. CS, DRT, i.t, LA, NT, Pmab, SRT, Tmab
84  2020 Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity. EVER, NP, PTX, UT-NPs
85  2020 DualWMDR: Detecting epistatic interaction with dual screening and multifactor dimensionality reduction. AMD, CD, MDR, PMI, SNPs
86  2020 Early Effects of Cyclophosphamide, Methotrexate, and 5-Fluorouracil on Neuronal Morphology and Hippocampal-Dependent Behavior in a Murine Model. CICIs, LTM
87  2020 Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy. ER, NATC
88  2020 Effectiveness of Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations. HER2, OS
89  2020 Effects of Exercise Interventions on Breast Cancer Patients During Adjuvant Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials. QL
90  2020 Effects of Nurse-Led Support Via WeChat, a Smartphone Application, for Breast Cancer Patients After Surgery: A Quasi-Experimental Study. apps, WSP
91  2020 Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. DD, HER2, PANTHER
92  2020 Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells. ---
93  2020 Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. TN
94  2020 Establishment and validation of an immunodiagnostic model for prediction of breast cancer. AUC, BBD, ELISA, NHC, TAAs
95  2020 Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. DEGs, ER, ESR1, KM, PgR, RFS
96  2020 Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. CAP, HR, LAP, NMA, ORR, OS, PFS, SUCRA, TRAS
97  2020 Evaluating the preoperative breast cancer characteristics affecting the accuracy of axillary ultrasound staging. ER, ILC, PR, US
98  2020 Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methods. BMD, DXA, FN, MOF, TBS
99  2020 Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment. HER2, NAC, pCR, PR, TN
100  2020 Evaluation of contrast-enhanced digital mammography (CEDM) in the preoperative staging of breast cancer: Large-scale single-center experience. CEDM, CI